Photo - Episome Biotechnologies
47453

Episome Biotechnologies

Episome Biotech focuses on industrial enzyme technologies

Turkey
Market: Chemistry, Paper, Another
Stage of the project: Operating business

Date of last change: 08.06.2020
Min investment
$  10.000.000
Show contacts
Total required
$ 10.000.000
Rating
equalizer из 1000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

Episome offers innovative and sustainable solutions which solve the paper industry's massive waste problem. Episome's newly developed patented technology, Epicellulyse XT, enables use of paper mill sludge (waste) in biogas/renewable energy and organic fertilizer production. Previously paper mill sludge was not suitable for biogas production due to its cellulose content.

Current Status

Episome has already developed Epicellulyse XT (Xerophilic Technology)'s lab scale prototype and also pilot plant on site. First contract has been signed to establish commercial facility in Netherlands. Episome has raised 1.7 Million Euros in 2017.

Market

Potential customers: Pulp and paper industries, biogas industries, green energy industries
Total addressable market is apprx. 0.5 Billion Euros for Europe, 1.4 Billion Euros for the globe. Episome aims to reach 5% in 5 years and 20% in 10 years. Market is growing 5-7% yearly with increasing life prosperity enhancement and growing online retailing.

Problem or Opportunity

Paper industry has a massive waste problem, pulp and paper industry is the 6th.largest polluter of the earth. Every year globally, 3 Billion Euros is spent for disposal of paper industry waste and related fines&fees. For a medium size plant this cost is nearly 7 Million Euros. Paper Industry needs an environment friendly, sustainable, profitable waste disposal method.

Solution (product or service)

Episome designs,develops and produces special biogas plants, based on its novel enzymatic pretreatment technology that solves this huge waste problem. Annually, Epicellulyse XT reduces 12M tons green house gases and saves 40.000*olympic-size swimming pools volume as not being landfill. Episome's new technology is market ready and contributes to paper industry for a strong PR. Today it's right time to invest for this circular economy solution.

Competitors

The main disposal routes for paper sludge are incineration in combined heat and power plants at the paper mill, producing paper sludge ash/GHGs or disposal to landfill. However,these disposing methods of paper sludge are temporary solutions due to their unsustainable,costly or environmentally unfriendly approaches. Epicellulyse XT has a reasonable CAPEX, verylittle
OPEX and the most important, we earn money,all others burn money! ROI is always less than 5 years and environment friendly.

Advantages or differentiators

Annually, Epicellulyse XT reduces 12M tons green house gases and saves 40.000*olympic-size swimming pools volume as not being landfill.Episome's new technology is market ready and contributes to paper industry for a
strong PR.Today it's right time to invest for this circular economy solution.

Finance

Episome will generate revenue by selling design&consulting services (0.05 Euros/mTon), advanced biogas plants (1.5 Euros/mTon) and our novel enzyme, Cellurise (24 Euros/mTon). Sale strategy is direct sale to paper mills, sales via strategic partners. Medium size one paper mill means 2.5 Million Euros revenue/year. Gross margin is nearly 60%.

Business model

Sale strategy is direct sale to paper mills, sales via strategic partners. Medium size one paper mill means 2.5 Million Euros revenue/year. Gross margin is nearly 60%.

Money will be spent on

Establishment of a demo facility in Europe

Team or Management

Won the competition and other awards

Energy Globe(National Winner), Global Cleantech Innovation Program 2017 - Los Angeles (1st.Rank-National Winner), 2016 TECHIN2B TECHARENA - Istanbul (1st. Rank), Falling Walls 2017 - Berlin, 2018, Invest Istanbul-London (Finalist)

Invention/Patent

Granted Patents: EPO (European Countries), Japan, USA, Indonesia, and South Korea

Photos

Photo 1 - Episome Biotech focuses on industrial enzyme technologies

Product Video

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility148
star1
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video